Actelion, J&J Return to the Negotiating table

The transcript discusses the negotiations between J&J and Italian, focusing on the potential acquisition and the conditions of a CVR payment. It highlights the strategic interests of J&J and Santa Fe in rare disease franchises and the market dynamics influencing these deals. The discussion also touches on potential future deals and the evolving antitrust landscape, suggesting that companies may find it easier to pursue mergers and acquisitions in the near future.

What was the main reason J&J increased their offer to Actelion?

• To expand into Asia

• To reduce their tax bill

• To acquire new technology

• To enter the rare disease market

Why is Actelion considered an attractive acquisition target?

• It has a strong presence in the Asian market

• It specializes in rare diseases

• It has a large number of patents

• It is a leader in digital health

Which company did Santa Fe lose to in a previous acquisition attempt?

• J&J

• Pfizer

• Roche

• Regeneron

What is a potential outcome of the changing antitrust environment?

• Industrial deals will become illegal

• Companies will be less worried about antitrust issues

• There will be fewer healthcare deals

• More companies will avoid mergers

Which of the following companies is mentioned as a potential target for J&J?

• Alexion

• Medivation

• Hasbro

• Honeywell